IRE1a INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT
AssigneeFosun Orinove Pharmatech, Inc.
InventorsQingping ZENG, John PATTERSON, Stephanie GREENE
Life of this patent
Estimating the term…
Abstract
Provided are a pharmaceutical combination comprising an IRE1α inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.
Claims33
A pharmaceutical combination, comprising
- (a) a compound of formula (I) or a pharmaceutically acceptable salt thereof, and (b) one or more additional cancer therapeutic agents:
- wherein
- R3 and R4 are independently hydrogen or C1-6 alkoxyl, which is optionally substituted with one or more substituents selected from the group consisting of (1) C1-C6 hydrocarbon chain containing N or O atom, and (2) C3-10 cycloalkyl, which optionally contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;
- R5 is hydrogen, C1-6 alkyl, C1-6 alkoxyl, or C1-6 alkylamino;
- R6 is C1-6 alkyl, which is substituted with 1, 2 or 3 substituents independently selected from the group consisting of C1-6 alkoxyl, C1-6 hydroxylalkyl, C1-6 alkoxyl C1-6alkyl,
- R9 and R10 are independently hydrogen;
- C1-6 alkyl;
- C1-6 alkoxyl C1-6 alkyl;
- perfluoro C1-6alkoxyl C1-6alkyl;
- or
- R9 and R10 together with the nitrogen atom to which they are attached form a heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and the heterocycle is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkylamino, C1-6 alkoxyl.
-10. (canceled)
-18. (canceled)
A method for enhancing the efficacy of a cancer therapeutic agent,
- comprising applying the compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with the cancer therapeutic agent,
- wherein
- R3 and R4 are independently hydrogen or C1-6 alkoxyl, which is optionally substituted with one or more substituents selected from the group consisting of (1) C1-C6 hydrocarbon chain containing N or O atom, and (2) C3-10 cycloalkyl, which optionally contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;
- R5 is hydrogen, C1-6 alkyl, C1-6 alkoxyl, or C1-6 alkylamino;
- R6 is C1-6 alkyl, which is substituted with 1, 2 or 3 substituents independently selected from the group consisting of C1-6 alkoxyl, C1-6 hydroxylalkyl, C1-6 alkoxyl C1-6alkyl,
- R9 and R10 are independently hydrogen;
- C1-6 alkyl;
- C1-6 alkoxyl C1-6 alkyl;
- perfluoro C1-6 alkoxyl C1-6alkyl;
- or
- R9 and R10 together with the nitrogen atom to which they are attached form a heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and the heterocycle is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkylamino, C1-6 alkoxyl.
-28. (canceled)
A method for treating cancerous tumors, comprising administering a subject in need thereof an effective amount of formula (I) or a pharmaceutically acceptable salt thereof:
- wherein
- R3 and R4 are independently hydrogen or C1-6 alkoxyl, which is optionally substituted with one or more substituents selected from the group consisting of (1) C1-C6 hydrocarbon chain containing N or O atom, and (2) C3-10 cycloalkyl, which optionally contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;
- R5 is hydrogen, C1-6 alkyl, C1-6 alkoxyl, or C1-6 alkylamino;
- R6 is C1-6 alkyl, which is substituted with 1, 2 or 3 substituents independently selected from the group consisting of C1-6 alkoxyl, C1-6 hydroxylalkyl, C1-6 alkoxyl C1-6alkyl,
- R9 and R10 are independently hydrogen;
- C1-6 alkyl;
- C1-6 alkoxyl C1-6 alkyl;
- perfluoro C1-6alkoxyl C1-6alkyl;
- or
- R9 and R10 together with the nitrogen atom to which they are attached form a heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and the heterocycle is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkylamino, C1-6 alkoxyl;
- and one or more additional cancer therapeutic agents.
-38. (canceled)
Dependencies are inferred from the claim text.